Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Orphagen discovers and develops small molecules to drug targets that have significant unrealized potential in areas of high clinical need. We focus on the unexplored or “orphan” members of the nuclear receptor family. Nuclear receptors have been a rich source of successful drugs. Orphagen has identified drug-like small molecules to several orphan nuclear receptors and has described efficacy in animal models of disease. An...
Orphagen discovers and develops small molecules to drug targets that have significant unrealized potential in areas of high clinical need. We focus on the unexplored or “orphan” members of the nuclear receptor family. Nuclear receptors have been a rich source of successful drugs. Orphagen has identified drug-like small molecules to several orphan nuclear receptors and has described efficacy in animal models of disease. An early success led to a partnership with Japan Tobacco (JT) Pharma to discover and develop oral drugs to treat psoriasis and other autoimmune diseases.

List your booth number for exhibitions, ask us